ReviewCanadian family physician Medecin de famille canadien2016
Update on the new 9-valent vaccine for human papillomavirus prevention.
Review in Canadian family physician Medecin de famille canadien, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Human Papillomavirus 16 E2 as an Apoptosis-Inducing Protein for Cancer Treatment: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.Epidemiology and infection · 2017Pooled it
- Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials.Journal of immunology research · 2017Pooled it
- Electronic Health Record Alerts for Early Human Papillomavirus Vaccination.JAMA network open · 2026Article
- Innovations in HPV vaccination and their role in global cervical cancer control: a review.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infectious agents and cancer · 2025Review
- Adolescent Attitudes Toward the Human Papillomavirus (HPV) Vaccine in Kocaeli, Turkiye.Cureus · 2025Article
- Article
- Assessing Saudi women's awareness about human papillomavirus (HPV) and their susceptibility to receive the vaccine.Human vaccines & immunotherapeutics · 2024Article
- Article
- Analyzing HPV Vaccination Service Preferences among Female University Students in China: A Discrete Choice Experiment.Vaccines · 2024Article
- HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women.Viruses · 2024Review
- Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.Ecancermedicalscience · 2024Review
- Multimodal Imaging in Diagnosing Multiple Evanescent White Dot Syndrome following Human Papillomavirus Vaccine Immunization.Case reports in ophthalmological medicine · 2024Article
- Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China.Human vaccines & immunotherapeutics · 2023Observational
- Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles.Biopolymers · 2023Review
- Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development.Biochimica et biophysica acta. General subjects · 2023Review
- Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer.Pharmaceutical research · 2023Review
- Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs.Frontiers in oncology · 2022Review
- Bibliometric analysis of global scientific literature on vaccine hesitancy in peer-reviewed journals (1990-2019).BMC public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo provide family physicians with information on the efficacy, safety, public health effects, and cost-effectiveness of the 9-valent human papillomavirus (HPV) vaccine. QUALITY OF EVIDENCE: Relevant publications in PubMed up to May 2015 were reviewed and analyzed. Most evidence cited is level I (randomized controlled trials and meta-analyses) or level II (cross-sectional, case-control, and epidemiologic studies). Government reports and recommendations are also referenced. MAIN MESSAGE: The 9-valent HPV vaccine, which protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, is safe and effective and will further reduce the incidence of HPV infection, as well as HPV-related cancers. It can also indirectly protect unvaccinated individuals through herd immunity. With an effective vaccination program, most cervical cancers can be prevented. Analyses show that the cost-effectiveness of the 9-valent HPV vaccine in female patients is comparable to the original quadrivalent HPV vaccine (which protects against HPV types 6, 11, 16, and 18) currently in use. However, the usefulness of vaccinating male patients with the 9-valent HPV vaccine needs further investigation.
conclusionThe 9-valent HPV vaccine offers more protection against HPV than the quadrivalent HPV vaccine does and is as safe. Analysis of cost-effectiveness favours its use, at least in adolescent girls. Therefore, physicians should recommend the 9-valent HPV vaccine to patients instead of the quadrivalent HPV vaccine.
Indexed as
Identifiers
27255620PMC4865336W2386602908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.